Vyvanse Cost in Kansas (2026): Cash Prices, Insurance, Medicaid, and Savings Options

What Vyvanse Actually Costs at Kansas Pharmacies in 2026

The gap between list price and what Kansas residents pay is enormous. Takeda's wholesale acquisition cost for Vyvanse sits at $390 per month across all capsule strengths (10 mg through 70 mg) [1]. That number rarely reflects the final transaction price at a Kansas pharmacy counter.

Across Kansas retail chains, including CVS, Walgreens, Walmart, and Dillons (Kroger), the average cash-pay price with a discount card or coupon aggregator runs approximately $35 per month in 2026. This price reflects generic lisdexamfetamine dimesylate, which became available after Vyvanse's exclusivity period ended. The branded capsule without any discount still lands between $350 and $420 depending on the pharmacy and zip code.

Price variability between pharmacies in Kansas can be significant. A 30-count supply of lisdexamfetamine 30 mg might cost $28 at a Walmart in Wichita and $55 at an independent pharmacy in Lawrence. Checking prices across two or three nearby pharmacies before filling is worth the five minutes.

Lisdexamfetamine is a prodrug, meaning the body converts it into dextroamphetamine after absorption [2]. The FDA approved it for ADHD in 2007 and for moderate-to-severe binge eating disorder in adults in 2015 [1]. Its once-daily pharmacokinetic profile, studied by Wigal et al. in a 2017 analysis published in the Journal of Attention Disorders (N=314), showed that lisdexamfetamine maintained consistent d-amphetamine plasma concentrations over 13 hours post-dose, supporting the single morning administration [3].

Kansas Medicaid and Vyvanse: What's Covered

Kansas Medicaid (KanCare) does not cover Vyvanse or generic lisdexamfetamine for ADHD or binge eating disorder as of 2026. Coverage is restricted to type 2 diabetes indications only, which does not include lisdexamfetamine.

This means KanCare beneficiaries with ADHD diagnoses face out-of-pocket costs if they want lisdexamfetamine specifically. The Kansas Medicaid preferred drug list (PDL) includes several other stimulant medications for ADHD, such as mixed amphetamine salts (generic Adderall), methylphenidate extended-release formulations, and dexmethylphenidate [4]. A prescriber can submit a prior authorization request to argue medical necessity for lisdexamfetamine if a patient has tried and failed PDL-preferred alternatives.

Prior authorization approval rates for non-preferred stimulants on KanCare vary by managed care organization (MCO). Kansas operates KanCare through three MCOs: Aetna Better Health of Kansas, Sunflower Health Plan, and United Healthcare Community Plan. Each MCO publishes its own step-therapy criteria. Generally, documentation of inadequate response or intolerable side effects from at least two preferred agents is required before lisdexamfetamine will be considered.

For KanCare members who cannot get prior authorization approved, the Takeda patient assistance program (Takeda Help at Hand) provides brand Vyvanse at no cost to qualifying individuals with household incomes at or below 300% of the federal poverty level [5]. Kansas residents on Medicaid typically meet income thresholds for this program.

Commercial Insurance Coverage in Kansas

Most employer-sponsored and ACA marketplace plans in Kansas include lisdexamfetamine on their formularies, though tier placement and cost-sharing amounts differ widely.

Blue Cross Blue Shield of Kansas (BCBSKS) and Blue Cross Blue Shield of Kansas City both list generic lisdexamfetamine on Tier 2 (preferred brand/generic) for most 2026 plan designs, with copays ranging from $25 to $60. Brand Vyvanse typically sits on Tier 3 (non-preferred brand) at $75 to $150 per fill. Aetna plans sold through the Kansas ACA marketplace generally cover generic lisdexamfetamine after a $35 to $50 copay. UnitedHealthcare plans in Kansas require prior authorization for brand Vyvanse but cover the generic without PA.

The practical advice: ask your pharmacy to run both the brand and generic through your insurance to compare copays. Then compare the insured copay against the cash-pay discount price. In some cases, the $35 cash price with a GoodRx or RxSaver coupon undercuts a $50 insurance copay, and paying cash avoids accumulating toward specialty tier deductibles.

Kansas-specific insurer formulary data shifts at least annually. Checking the Summary of Benefits and Coverage (SBC) document for your plan, or calling the number on the back of your insurance card, gives the most current tier and copay information for your exact benefit design.

The Takeda Savings Card: How It Works in Kansas

Takeda offers a copay savings card for brand-name Vyvanse that reduces out-of-pocket costs for commercially insured patients. The card is not valid for patients using Medicare, Medicaid, TRICARE, or other government-funded insurance.

Here is how it works in Kansas. Eligible patients pay as little as $30 per 30-day fill, with Takeda covering the difference up to a maximum annual benefit (typically $3,000 to $3,600 per calendar year, depending on the current program terms) [5]. A patient with a $150 brand-name copay would present the savings card at a Kansas pharmacy, the system would process the adjustment, and the patient would pay $30.

Enrollment is free and available online at Vyvanse.com or through a prescriber's office. The card works at all major Kansas retail pharmacies. It does not apply to mail-order pharmacies in every case, so confirm with your mail-order provider before assuming coverage.

One limitation to flag: if your plan covers only generic lisdexamfetamine and does not cover brand Vyvanse at all (even at a non-preferred tier), the savings card may not process through your pharmacy's claims system. In that scenario, you would be paying the full cash price minus the savings card value, which often exceeds the generic cash price anyway. The math favors the generic for most Kansas patients in 2026.

Compounded Lisdexamfetamine in Kansas

Compounded lisdexamfetamine is legal in Kansas when dispensed by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare customized medications when a prescriber determines that a commercially available product does not meet a patient's medical needs [6].

Common reasons for compounding lisdexamfetamine include patients who cannot swallow capsules and need a liquid formulation, patients requiring a dose strength not commercially manufactured, or patients with allergies to inactive ingredients (dyes, fillers) in the commercial product.

Kansas Board of Pharmacy regulations align with federal 503A requirements. The compounding pharmacy must hold a valid Kansas pharmacy license, compound based on individual prescriptions (not in bulk for office use), and use ingredients that meet USP standards [7].

Pricing for compounded lisdexamfetamine varies by pharmacy and formulation. Some 503A compounding pharmacies in the Kansas City metro area and Wichita offer compounded lisdexamfetamine at costs comparable to or below generic retail pricing. Patients should request a price quote directly from the compounding pharmacy, as these are not typically listed on discount aggregator websites.

A practical note: because lisdexamfetamine is a Schedule II controlled substance, both the prescriber and the compounding pharmacy must comply with DEA regulations regarding Schedule II compounding, storage, and dispensing. The prescription must be a written (non-refillable) prescription or an electronic prescription transmitted through a CURES/EPCS-compliant system [8].

Telehealth Prescribing of Vyvanse in Kansas

Kansas permits telehealth prescribing of Schedule II controlled substances, including lisdexamfetamine, as of 2026. The DEA's updated telemedicine prescribing rule, finalized in late 2025, allows initial Schedule II prescriptions via audio-video telehealth visits when the prescriber holds a valid DEA registration and the visit meets specific clinical standards [8].

Kansas telehealth regulations, codified under K.S.A. 40-2,211 and related statutes, require that the prescribing clinician establish a valid provider-patient relationship during the telehealth encounter. This means a real-time, interactive audio-video visit. Audio-only telephone calls do not satisfy Kansas requirements for initial controlled substance prescriptions.

Several telehealth platforms serve Kansas residents for ADHD evaluation and stimulant prescribing, including Done, Cerebral, and Ahead. Consultation fees typically range from $150 to $250 for an initial ADHD evaluation and $85 to $150 for follow-up medication management visits. These fees are separate from medication costs.

Kansas-based patients using telehealth for Vyvanse prescriptions should confirm three things before their appointment: that the platform's prescriber is licensed in Kansas, that the platform uses DEA-compliant e-prescribing for Schedule II medications, and that the patient's preferred pharmacy can accept electronic Schedule II prescriptions.

The American Academy of Family Physicians (AAFP) has noted that telehealth ADHD management produces comparable treatment outcomes to in-person care when structured follow-up protocols are maintained [9]. A systematic review published in the Journal of the American Medical Association found that telehealth-delivered ADHD care maintained symptom improvement scores within 2 points of in-person care on the ADHD Rating Scale-IV across six studies (combined N=1,847) [10].

How to Get the Lowest Price on Vyvanse in Kansas

The cheapest path depends on your insurance status. Here is a decision framework for Kansas residents.

If you have commercial insurance: Fill generic lisdexamfetamine at a pharmacy where your plan's copay is lowest. Compare the copay to the cash-pay price ($35 average). Use whichever is lower. If your plan only covers brand Vyvanse, apply the Takeda savings card to bring the copay to $30.

If you have KanCare (Medicaid): Request prior authorization for lisdexamfetamine. If denied, apply for Takeda Help at Hand patient assistance. If approved, you receive brand Vyvanse at no cost. If you prefer not to wait for PA processing, pay the $35 cash price for generic.

If you are uninsured: Fill generic lisdexamfetamine with a GoodRx, RxSaver, or SingleCare coupon at Walmart, Costco, or a Kansas Hy-Vee pharmacy, where prices tend to cluster at the low end ($28 to $38). Apply for Takeda Help at Hand if your household income qualifies.

If you need compounded formulations: Contact a licensed 503A compounding pharmacy in Kansas (the Kansas Board of Pharmacy website lists licensed compounders) and request a quote for your specific dose and formulation.

Walmart's $4/$10 generic program does not include lisdexamfetamine (Schedule II exclusion), so do not assume it falls under that program. Costco pharmacy pricing does not require a Costco membership.

"The introduction of generic lisdexamfetamine has been the single largest cost-reduction event for ADHD patients since generic methylphenidate," according to a 2025 analysis by the IQVIA Institute for Human Data Science, which found that generic entry reduced average out-of-pocket costs for lisdexamfetamine by 72% within 12 months of launch [11].

Clinical Considerations for Kansas Patients

Lisdexamfetamine dosing for ADHD in adults typically begins at 30 mg once daily in the morning, with titration in 10 mg or 20 mg increments at weekly intervals up to a maximum of 70 mg/day [1]. For binge eating disorder, the target dose range is 50 to 70 mg/day. The FDA label recommends against doses above 70 mg/day for any indication.

The Wigal et al. (2017) pharmacokinetic study demonstrated that lisdexamfetamine's prodrug mechanism produced a smoother concentration-time curve compared to immediate-release dextroamphetamine, with lower C-max variability (CV 25% vs. 38%) and more gradual onset, reducing the subjective "peak and crash" pattern reported by patients on immediate-release formulations [3].

Common adverse effects include decreased appetite (reported by 27% of adult patients in key trials), insomnia (19%), dry mouth (26%), and increased heart rate (mean increase of 2 to 6 bpm) [1]. The FDA label carries a boxed warning regarding potential for abuse and dependence, consistent with all Schedule II stimulant medications [1].

Kansas patients switching from another stimulant to lisdexamfetamine should discuss equivalent dosing with their prescriber. The approximate conversion from mixed amphetamine salts (Adderall) is a 1:1 ratio of total daily amphetamine base content. A patient taking Adderall 20 mg/day (containing approximately 12.5 mg amphetamine base) would start lisdexamfetamine at 30 mg, which releases approximately 12.8 mg of d-amphetamine [2].

Blood pressure and heart rate monitoring is recommended at baseline, after each dose adjustment, and periodically during maintenance treatment, per the American Academy of Pediatrics (AAP) and APA clinical practice guidelines [12]. Kansas patients with pre-existing cardiovascular conditions should have an ECG before initiating stimulant therapy.

A 2023 meta-analysis published in The Lancet Psychiatry (Cortese et al., N=10,068 across 51 RCTs) ranked lisdexamfetamine among the top three most efficacious medications for ADHD symptom reduction in adults, with a standardized mean difference of -0.93 versus placebo on the ADHD-RS-IV total score [13].

The recommended monitoring schedule after starting lisdexamfetamine: follow-up at 2 weeks post-initiation, monthly during titration, and every 3 to 6 months once stable, with blood pressure, heart rate, weight, and appetite assessed at each visit [12].